Marta Padovan

Padova, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 55 publications

Prognostic impact of phosphatase and tensin homolog status in recurrent IDH-wildtype glioblastoma receiving second-line therapy.

Prognostic impact of phosphatase and tensin homolog status in recurrent IDH-wildtype glioblastoma receiving second-line therapy.

Journal: Neuro-oncology advances
Published: April 17, 2026

BRAF-altered glioma in adults and children: A Society for Neuro-Oncology (SNO) and European Society for Neuro-Oncology (EANO) consensus review on clinical management and future directions.

BRAF-altered glioma in adults and children: A Society for Neuro-Oncology (SNO) and European Society for Neuro-Oncology (EANO) consensus review on clinical management and future directions.

Journal: Neuro-oncology
Published: March 09, 2026

Prolonged sequential temozolomide in glioblastoma: A systematic review with exploratory quantitative synthesis.

Prolonged sequential temozolomide in glioblastoma: A systematic review with exploratory quantitative synthesis.

Journal: Cancer treatment and research communications
Published: February 17, 2026

Reasons driving choice and clinical course of patients with CNS WHO grade 3 IDH mutant glioma receiving vorasidenib after surgery: a pilot experience.

Reasons driving choice and clinical course of patients with CNS WHO grade 3 IDH mutant glioma receiving vorasidenib after surgery: a pilot experience.

Journal: Journal of neuro-oncology
Published: January 08, 2026

Targeted and systemic therapies for recurrent adult ependymomas: real-world outcomes from a single institution and concise literature review.

Targeted and systemic therapies for recurrent adult ependymomas: real-world outcomes from a single institution and concise literature review.

Journal: Frontiers in oncology
Published: November 17, 2025

Targeted therapies in optic pathway gliomas.

Targeted therapies in optic pathway gliomas.

Journal: Cancer treatment reviews
Published: November 13, 2025

TET CpG sequence-context-specific DNA demethylation shapes progression of IDH-mutant gliomas.

TET CpG sequence-context-specific DNA demethylation shapes progression of IDH-mutant gliomas.

Journal: Cell reports. Medicine
Published: September 09, 2025

Tumor-initiating genetics and therapy drive divergent molecular evolution in IDH-mutant gliomas.

Tumor-initiating genetics and therapy drive divergent molecular evolution in IDH-mutant gliomas.

Journal: bioRxiv : the preprint server for biology
Published: August 12, 2025

Regorafenib versus local standard of care in patients with grade 2-3 meningioma no longer eligible for loco-regional treatments: a phase II randomized controlled trial (the MIRAGE study).

Regorafenib versus local standard of care in patients with grade 2-3 meningioma no longer eligible for loco-regional treatments: a phase II randomized controlled trial (the MIRAGE study).

Journal: Trials
Published: February 17, 2025

Bevacizumab in recurrent glioblastoma: does dose matter? Our monocentric and comparative experience.

Bevacizumab in recurrent glioblastoma: does dose matter? Our monocentric and comparative experience.

Journal: Journal of neuro-oncology
Published: January 27, 2025

The role of meningioma integrated molecular profiling to improve patient management and disclose novel therapeutic targets.

The role of meningioma integrated molecular profiling to improve patient management and disclose novel therapeutic targets.

Journal: Brain communications
Published: January 16, 2025

Corrigendum to "PARP inhibitors in gliomas: Mechanisms of action, current trends and future perspectives" [Cancer Treat. Rev. 131 (2024) 102850].

Corrigendum to "PARP inhibitors in gliomas: Mechanisms of action, current trends and future perspectives" [Cancer Treat. Rev. 131 (2024) 102850].

Journal: Cancer treatment reviews
Published: December 21, 2024
Showing 1-12 of 55

Last Updated: 09/26/2026